In this study, we describe the advancement of a gene therapy that combines TrkB and BDNF to offer a synergistic approach to glaucoma treatment by simultaneously addressing the limitations of BDNF monotherapy and enhancing TrkB receptor activity. Here, NTRK2 is linked to glaucoma.